miR-217、USP10、LZTS1在晚期非小细胞肺癌癌组织与癌旁组织中的表达及与临床疗效的关系  

Expression of miR-217,USP10 and LZTS1 in Advanced Non-small Cell Lung Cancer Tissues and Adjacent Tissues and Their Relationship with Clinical Efficacy

作　　者：谢芳芳 樊静 李建梅 XIE Fangfang;FAN Jing;LI Jianmei(Department of Laboratory,Tianjin Cancer Hospital Qinhuangdao Hospital,Qinhuangdao,Hebei 066000,China;Department of General Oncology,Tianjin Cancer Hospital Qinhuangdao Hospital,Qinhuangdao,Hebei 066000,China)

机构地区：[1]天津市肿瘤医院秦皇岛医院检验科,河北秦皇岛066000 [2]天津市肿瘤医院综合肿瘤科,河北秦皇岛066000

出　　处：《临床误诊误治》2025年第8期73-79,共7页Clinical Misdiagnosis & Mistherapy

基　　金：河北省2021年度医学科学研究课题项目(20210772);秦皇岛市重点研发计划科技支撑项目(202401A133)。

摘　　要：目的探讨微小核糖核酸-217(miR-217)、泛素特异性肽酶10(USP10)、亮氨酸拉链肿瘤抑制基因1(LZTS1)在晚期非小细胞肺癌(NSCLC)癌组织与癌旁组织中的表达及与临床疗效的关系。方法选取2021年1月至2023年1月收治的晚期NSCLC患者108例作为研究对象,比较癌组织与癌旁组织中miR-217、USP10、LZTS1水平:均给予个体化治疗,根据1年后随访病情分为疾病控制组与疾病进展组,比较2组临床资料及癌组织miR-217、USP10、LZTS1水平,分析miR-217、USP10、LZTS1水平与临床疗效的关系及预测价值,对比不同miR-217、USP10、LZTS1表达患者1年生存率。结果晚期NSCLC患者癌组织miR-217、LZTS1 mRNA低于癌旁组织,USP10 mRNA高于癌旁组织(P<0.01);108例晚期NSCLC患者经治疗后,将44例部分缓解患者和33例稳定患者纳入疾病控制组,31例进展患者纳入疾病进展组;疾病进展组癌组织miR-217、LZTS1 mRNA低于疾病控制组,USP10 mRNA高于疾病控制组(P<0.01);多因素logistic回归分析显示,在校正其他因素前后,miR-217、USP10、LZTS1均是晚期NSCLC患者临床疗效的独立影响因素(P<0.01)。癌组织miR-217、USP10、LZTS1联合预测晚期NSCLC患者疾病进展的价值明显高于各指标单独预测(P<0.05)。Kaplan-Meier曲线分析显示,miR-217、LZTS1低表达患者1年生存率为35.00%(14/40)、31.71%(13/41)低于高表达患者的69.70%(46/66)、72.31%(47/65),USP10高表达患者1年生存率为32.61%(15/46)低于低表达患者的75.00%(45/60),差异有统计学意义(P<0.05)。结论miR-217、LZTS1在晚期NSCLC患者癌组织中呈低表达,USP10呈高表达,三者与其临床疗效独立相关,能有效预测临床疗效,且与生存预后联系紧密。Objective To investigate the expression of microrNA-217(miR-217),ubiquitin-specific peptidase 10(USP10)and leucine zipper tumor suppressor gene 1(LZTS1)in advanced non-small cell lung cancer(NSCLC)tissues and adjacent tissues and their relationship with clinical efficacy.Methods A total of 108 patients with advanced NSCLC admitted from January 2021 to January 2023 were selected as the research subjects,and the levels of miR-217,USP10 and LZTS1 in cancer tissues and adjacent tissues were compared.All patients were given individualized treatment,and were divided into disease control group and disease progression group based on the condition at 1-year follow-up.The clinical data and the levels of miR-217,USP10 and LZTS1 in cancer tissues of the two groups were compared,and the relationship between the levels of miR-217,USP10 and LZTS1 and clinical efficacy and its predictive value were analyzed.The 1-year survival rates of patients with different levels of miR-217,USP10 and LZTS1 were compared.Results The mRNA levels of miR-217 and LZTS1 in cancer tissues of patients with advanced NSCLC were lower than those in adjacent tissues,and USP10 mRNA level was higher than that in adjacent tissues(P<0.01).Among 108 patients with advanced NSCLC,44 patients with partial response and 33 patients with stable disease were included in the disease control group,and 31 patients with progression were included in the disease progression group.The miR-217 and LZTS1 mRNA levels in cancer tissues of the disease progression group were lower than those of the disease control group,and USP10 mRNA level was higher than that of the disease control group(P<0.01).Multivariate logistic regression analysis showed that miR-217,USP10 and LZTS1 were independent factors affecting the clinical efficacy of advanced NSCLC patients before and after adjusting for other factors(P<0.01).The combination of miR-217,USP10,and LZTS1 in cancer tissues had a significantly higher value in predicting the disease progression of advanced NSCLC patients than each inde

关 键 词：肺肿瘤 非小细胞 晚期 微小核糖核酸-217 泛素特异性肽酶10 亮氨酸拉链肿瘤抑制基因1 临床疗效 预测价值 生存曲线 

分 类 号：R734.2[医药卫生—肿瘤]